StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

GSK Pharma (GLAXO)

Pharma · NSE · end-of-day 2026-10-19

₹2,495.40

Day change

-2.76%

1-year

-9.6%

From 52-week high

-19.7%

Weinstein stage

Stage 1

Minervini template

4/8

GSK Pharma closed at ₹2,495.40 on 2026-10-19, down 10% over the past year, 20% below its 52-week high. It meets 4 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 1 - basing; on earnings, it passes 0 of 5 SEPA checks. Over the year its annualised volatility was about 26%, with a largest fall of 24% from a peak.

About GSK Pharma

GlaxoSmithKline Pharmaceuticals Limited develops and markets prescription medicines, vaccines, and specialty healthcare products across multiple therapeutic segments. The company leverages global scientific research to deliver innovative healthcare solutions in India. Product quality and physician trust strengthen market positioning. Expansion of preventive healthcare supports vaccine demand. Innovation remains central to long-term business growth.

Price, RSI and MACD

6M1Y2Y3Y

Price · +2.7% over the period

RSI (14) · 30.2

MACD (12, 26, 9) · histogram -19.15

Price · -9.8% over the period

RSI (14) · 30.2

MACD (12, 26, 9) · histogram -19.15

Price · -9.3% over the period

RSI (14) · 30.2

MACD (12, 26, 9) · histogram -19.15

Price · +63.7% over the period

RSI (14) · 30.2

MACD (12, 26, 9) · histogram -19.15

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	ROE previous year	ROCE	Debt / equity	Free cash flow	EV / EBITDA	Beta
₹42,275 cr	₹3,955 cr	₹1,068 cr	40.2	62.01	18.64	49.1%	49.8%	66.5%	0.00	₹849 cr	28.7	0.46

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	938	237	14.00	+15.7%	+16.6%	25.3%
Mar 2026	995	278	16.40	+5.7%	+2.1%	27.9%
Dec 2025	1,041	296	16.54	+21.9%	+9.7%	28.4%
Sep 2025	980	258	15.07	+2.7%	-3.0%	26.3%
Jun 2025	805	205	12.10	+12.4%	-1.2%	25.5%
Mar 2025	974	263	15.52	+35.2%	+4.8%	27.0%
Dec 2024	949	230	13.57	+37.2%	+17.9%	24.2%
Sep 2024	1,011	252	14.67	+14.2%	+5.6%	25.0%

Consolidated · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 0 of 5 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	✗ Fail
EPS growth accelerating over 3 quarters	✗ Fail
Sales up 25%+, or sales growth accelerating	✗ Fail
Annual EPS up 25%+ in each of the last 2 years	✗ Fail
Net margin above the same quarter last year	✗ Fail

Investor methods

Method	Checks	Score	Verdict
Minervini	✗ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✗ At least 25% above the 52-week low · low 2,103.20 ✓ Within 25% of the 52-week high · high 3,106.40 ✗ RS percentile 70 or more · RS 50 Trend template - the gate, measured: a modest 21-day edge.	4/8	4 of 8
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 1 - basing
CAN SLIM	✗ C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 3,106.40 ✓ S more volume on up days than down days (50 sessions) · 2.60x ✗ L RS percentile 80 or more · RS 50 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist.	2/6	Weak
Darvas	✓ Box top confirmed (3 sessions below the new high) · top 3,120.70 ✓ Box bottom confirmed (3 sessions holding) · bottom 2,485.00 ✗ Close above the box top · close 2,495.40 ✗ Volume at least 1.5x its 50-day average · 0.2x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high.	39/100	In box
Turtle	✗ Close above the prior 55-session high · 3,120.70 ✗ Close above the prior 20-session high · 2,987.00 ✗ Close below the prior 20-session low · 2,485.00 Donchian channel breakout - the Turtle traders' entry.		No signal
Greenblatt	— Earnings yield (EBITDA / EV) · 3.5% — Return on capital (ROCE) · 66.5% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately.	67/100	Average
Graham	✗ Price at or below the Graham number · Graham number 432.18 ✗ P/E 15 or less · P/E 40.2 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 18.64 ✓ Current ratio 2 or more · 2.13 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	17/100	Expensive
Piotroski	✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✓ ROA rising ✗ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✓ Current ratio rising · 2.13 ✓ No new shares issued ✓ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026.	7/9	Strong

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
GLAXO this stock	-12.1	+0.5	+2.7	-9.0	+62.4	+70.3	40.2	18.64	49.1	66.5	—	0.00	28.7	42,275	3,955	1,068	62.0	0.46
BLISSGVS	-8.0	+29.9	+147.2	+312.3	+606.5	+476.9	48.7	5.57	11.5	16.8	—	0.00	29.3	6,650	1,005	142	12.9	1.10
VENUSREM	+0.7	-5.9	+55.8	+252.6	+518.8	+242.4	18.3	3.21	16.8	21.9	—	0.00	13.7	2,130	811	116	86.9	0.88
INDSWFTLAB	-5.7	+50.4	+153.3	+247.2	+287.1	+472.2	51.6	2.21	3.2	3.9	—	0.01	33.4	3,056	665	57	6.8	0.78
MOREPENLAB	+0.5	+108.6	+194.2	+152.6	+242.7	+132.7	47.5	5.34	7.9	10.1	—	0.16	40.2	6,657	1,951	140	2.6	1.46
SHILPAMED	-14.2	+40.1	+113.1	+146.1	+421.3	+189.7	57.3	6.61	9.8	11.4	—	0.25	—	17,130	1,682	297	15.3	0.87
RUBICON	-15.1	-1.7	+60.3	+140.3	—	—	83.8	19.08	22.4	—	—	0.20	61.3	24,587	1,936	288	17.7	0.34
LAURUSLABS	+5.9	+32.7	+83.2	+129.9	+421.9	+235.3	88.9	21.09	18.2	17.9	—	0.45	62.0	1.12L	8,839	1,252	23.3	0.74
ZIMLAB	+2.0	+14.2	+73.3	+101.9	+17.5	—	168.5	2.50	2.1	5.5	—	0.42	21.1	740	397	4	0.8	0.75
ACUTAAS	-5.4	-11.0	+35.0	+97.5	—	—	69.0	16.11	24.0	31.7	—	0.02	49.9	26,636	1,462	387	47.2	0.77
IOLCP	-9.8	+17.8	+108.9	+87.8	+99.0	+56.2	32.0	2.99	7.9	10.7	—	0.07	20.7	5,376	2,524	168	5.7	1.13

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

Ajanta Pharma Anthem Biosciences Limited IPCA Laboratories Gland Pharma Emcure Pharmaceuticals Limited Abbott India Biocon Wockpharma

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact